Want to see HK:2616 full AI Analyst Report?
CStone Pharmaceuticals (2616) Ratios
CStone Pharmaceuticals Ratios
HK:2616's free cash flow for Q2 2026 was $-221.57M. For the 2026 fiscal year, HK:2616's free cash flow was increased by $4.00 and operating cash flow was $-221.57M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.18 | 1.60 | 1.56 | 1.32 | 2.10 |
| Quick Ratio | 1.95 | 1.18 | 1.44 | 1.29 | 2.03 |
| Cash Ratio | 1.48 | 0.57 | 1.17 | 0.59 | 0.80 |
| Solvency Ratio | -0.53 | -0.07 | -0.26 | -0.72 | -1.78 |
| Operating Cash Flow Ratio | -0.64 | -0.50 | -0.69 | -0.65 | -1.59 |
| Short-Term Operating Cash Flow Coverage | -1.76 | -5.64 | -5.56 | -71.49 | -48.34 |
| Net Current Asset Value | $ 372.07M | $ 60.31M | $ 124.62M | $ 57.82M | $ 893.20M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.26 | 0.26 | 0.22 | 0.17 | 0.08 |
| Debt-to-Equity Ratio | 0.57 | 0.98 | 0.80 | 0.64 | 0.14 |
| Debt-to-Capital Ratio | 0.36 | 0.49 | 0.44 | 0.39 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.20 | 0.41 | 0.32 | 0.33 | 0.09 |
| Financial Leverage Ratio | 2.20 | 3.83 | 3.64 | 3.65 | 1.88 |
| Debt Service Coverage Ratio | -1.94 | -1.01 | -2.52 | -53.48 | -59.58 |
| Interest Coverage Ratio | -33.46 | -6.05 | -51.24 | -107.60 | -815.99 |
| Debt to Market Cap | 0.05 | 0.12 | 0.12 | 0.05 | 0.02 |
| Interest Debt Per Share | 0.26 | 0.29 | 0.30 | 0.25 | 0.15 |
| Net Debt to EBITDA | 1.09 | 0.42 | 2.13 | 0.32 | 0.30 |
| Profitability Margins | |||||
| Gross Profit Margin | 19.01% | 58.98% | 65.60% | 57.83% | 56.17% |
| EBIT Margin | -154.25% | -23.42% | -76.62% | -185.76% | -786.92% |
| EBITDA Margin | -137.93% | -18.77% | -64.08% | -176.51% | -777.62% |
| Operating Profit Margin | -160.48% | -22.52% | -130.55% | -189.49% | -750.64% |
| Pretax Profit Margin | -157.26% | -22.40% | -79.17% | -187.53% | -787.84% |
| Net Profit Margin | -162.10% | -22.40% | -79.17% | -187.53% | -787.84% |
| Continuous Operations Profit Margin | -162.10% | -22.40% | -79.17% | -187.53% | -787.84% |
| Net Income Per EBT | 103.08% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.99% | 99.47% | 60.64% | 98.96% | 104.96% |
| Return on Assets (ROA) | -32.16% | -6.55% | -22.10% | -55.09% | -84.53% |
| Return on Equity (ROE) | -70.82% | -25.07% | -80.39% | -200.90% | -159.08% |
| Return on Capital Employed (ROCE) | -50.99% | -12.89% | -74.61% | -131.82% | -136.68% |
| Return on Invested Capital (ROIC) | -41.59% | -11.39% | -63.68% | -123.79% | -132.33% |
| Return on Tangible Assets | -36.14% | -7.40% | -24.66% | -61.04% | -87.24% |
| Earnings Yield | -6.65% | -3.31% | -14.26% | -18.83% | -24.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.97 | 3.11 | 2.69 | 6.24 | 2.07 |
| Payables Turnover | 2.83 | 0.49 | 0.65 | 0.70 | 0.26 |
| Inventory Turnover | 1.87 | 0.58 | 1.47 | 9.15 | 1.74 |
| Fixed Asset Turnover | 3.24 | 3.12 | 3.02 | 2.33 | 1.30 |
| Asset Turnover | 0.20 | 0.29 | 0.28 | 0.29 | 0.11 |
| Working Capital Turnover Ratio | 0.53 | 0.92 | 1.19 | 0.73 | 0.13 |
| Cash Conversion Cycle | 112.17 | 3.84 | -178.98 | -423.83 | -1029.69 |
| Days of Sales Outstanding | 45.80 | 117.31 | 135.69 | 58.49 | 176.12 |
| Days of Inventory Outstanding | 195.49 | 625.11 | 248.97 | 39.90 | 209.65 |
| Days of Payables Outstanding | 129.11 | 738.58 | 563.64 | 522.21 | 1415.46 |
| Operating Cycle | 241.28 | 742.42 | 384.66 | 98.38 | 385.77 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.24 | -0.27 | -0.47 | -0.52 | -1.28 |
| Free Cash Flow Per Share | -0.24 | -0.27 | -0.52 | -0.61 | -1.40 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -9.05 | -6.02 | -9.95 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -9.05 | -6.02 | -9.95 |
| Operating Cash Flow Coverage Ratio | -0.94 | -0.96 | -1.62 | -2.14 | -8.52 |
| Operating Cash Flow to Sales Ratio | -1.22 | -0.84 | -1.27 | -1.27 | -6.09 |
| Free Cash Flow Yield | -4.99% | -12.45% | -25.39% | -14.90% | -20.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -15.27 | -30.23 | -7.01 | -5.31 | -4.08 |
| Price-to-Sales (P/S) Ratio | 24.38 | 6.77 | 5.55 | 9.96 | 32.16 |
| Price-to-Book (P/B) Ratio | 10.65 | 7.58 | 5.64 | 10.67 | 6.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -20.05 | -8.03 | -3.94 | -6.71 | -4.80 |
| Price-to-Operating Cash Flow Ratio | -20.05 | -8.03 | -4.37 | -7.83 | -5.28 |
| Price-to-Earnings Growth (PEG) Ratio | -0.05 | 0.40 | 0.11 | 0.10 | -0.10 |
| Enterprise Value Multiple | -16.58 | -35.65 | -6.53 | -5.32 | -3.84 |
| Enterprise Value | 6.17B | 2.72B | 1.94B | 4.52B | 7.27B |
| EV to EBITDA | -16.58 | -35.65 | -6.53 | -5.32 | -3.84 |
| EV to Sales | 22.87 | 6.69 | 4.19 | 9.39 | 29.83 |
| EV to Free Cash Flow | -18.82 | -7.94 | -2.97 | -6.33 | -4.45 |
| EV to Operating Cash Flow | -18.82 | -7.94 | -3.30 | -7.38 | -4.90 |
| Tangible Book Value Per Share | 0.34 | 0.16 | 0.22 | 0.25 | 0.98 |
| Shareholders’ Equity Per Share | 0.44 | 0.29 | 0.36 | 0.38 | 1.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.03 | 0.00 | 0.00 | -0.07 | -0.04 |
| Revenue Per Share | 0.19 | 0.32 | 0.37 | 0.41 | 0.21 |
| Net Income Per Share | -0.31 | -0.07 | -0.29 | -0.77 | -1.65 |
| Tax Burden | 1.03 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 0.96 | 1.03 | 1.01 | 1.00 |
| Research & Development to Revenue | 1.16 | 0.33 | 1.14 | 1.28 | 5.35 |
| SG&A to Revenue | 0.64 | 0.41 | 0.11 | 0.13 | 0.45 |
| Stock-Based Compensation to Revenue | 0.09 | -0.01 | 0.08 | 0.30 | 0.91 |
| Income Quality | 0.77 | 3.76 | 1.60 | 0.68 | 0.77 |
Currency in CNY